A New Vaccine for Advanced Pancreatic Cancer
An mRNA vaccine that works against KRAS mutations is being tested with and without immunotherapy for advanced or metastatic pancreatic cancer.
COMBATing Pancreatic Cancer
Dr. Manuel Hidalgo explains the COMBAT trial, which combines immunotherapy, a checkpoint inhibitor, and chemotherapy to attack pancreatic cancer.
Pancreatic Microbiome May Hold the Key To Better Treatment
Dr. Deirdre Cohen’s research into the pancreatic microbiome has found that gut bacteria may directly influence the effectiveness of immunotherapy.
Genomic Profiling of my Pancreatic Cancer Gave me a New Lease on Life
When standard treatment did not work for Roy Vinke’s pancreatic cancer, he had genomic profiling done. A mutation was found, changing his treatment plan.
Molecular Profiling: Getting to Know Your Tumor
Dr. Johanna Bendell explains the value of molecular profiling. It can indicate which type of chemotherapy will be more successful on your tumor.
Immunotherapy for Pancreatic Neuroendocrine Tumors
This trial is active, but no longer recruiting participants. Pancreatic neuroendocrine tumors (P-NETs) make up less than 5 percent of all pancreatic cancers. Unlike pancreatic ductal adenocarcinomas (PDAs), P-NETs originate in the hormone-making islet cells of the pancreas, respond to different treatments, and have an overall survival rate higher than PDAs. In a clinical trial,…
Keytruda Runner-Up for Science Breakthrough of the Year
The Lustgarten Foundation shares the story that Keytruda (pembrolizumab) is a runner-up in Science magazine’s Breakthrough of the year.
Chemotherapy, Immunotherapy, and Radiation for Locally Advanced Pancreatic Cancer
A clinical trial is testing chemotherapy that enhances the action of two immunotherapy drugs and SBRT to stop locally advanced pancreatic cancer.
Presurgical Treatment for Pancreatic Cancer That Is Removable
A clinical trial looks at immunotherapy plus vitamin D plus standard chemotherapy before surgery to remove pancreatic cancer.
An Immunotherapy Game Changer
Immunotherapy with Keytruda (pembrolizumab) is approved for use in cancer patients with certain genetic defects in their tumors.